With the development of molecular biology technology and MM-related molecular biology research, targeted therapies (BRAF inhibitors, KIT inhibitors, bevacizumab, and MEK inhibitors) have been slowly implemented in clinical trials, which have been approved by the US Food and Drug Administration (FDA) for the treatment of MM. This evidence concerns the gene KIT and Miyoshi myopathy.